Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2007 Oct;48(10):1724-32.
doi: 10.2967/jnumed.107.040279. Epub 2007 Sep 14.

PET studies of d-methamphetamine pharmacokinetics in primates: comparison with l-methamphetamine and ( --)-cocaine

Affiliations
Comparative Study

PET studies of d-methamphetamine pharmacokinetics in primates: comparison with l-methamphetamine and ( --)-cocaine

Joanna S Fowler et al. J Nucl Med. 2007 Oct.

Abstract

The methamphetamine molecule has a chiral center and exists as 2 enantiomers, d-methamphetamine (the more active enantiomer) and l-methamphetamine (the less active enantiomer). d-Methamphetamine is associated with more intense stimulant effects and higher abuse liability. The objective of this study was to measure the pharmacokinetics of d-methamphetamine for comparison with both l-methamphetamine and (-)-cocaine in the baboon brain and peripheral organs and to assess the saturability and pharmacologic specificity of binding.

Methods: d- and l-methamphetamine and (-)-cocaine were labeled with (11)C via alkylation of the norprecursors with (11)C-methyl iodide using literature methods. Six different baboons were studied in 11 PET sessions at which 2 radiotracer injections were administered 2-3 h apart to determine the distribution and kinetics of (11)C-d-methamphetamine in brain and peripheral organs. Saturability and pharmacologic specificity were assessed using pretreatment with d-methamphetamine, methylphenidate, and tetrabenazine. (11)C-d-Methamphetamine pharmacokinetics were compared with (11)C-l-methamphetamine and (11)C-(-)-cocaine in both brain and peripheral organs in the same animal.

Results: (11)C-d- and l-methamphetamine both showed high uptake and widespread distribution in the brain. Pharmacokinetics did not differ between enantiomers, and the cerebellum peaked earlier and cleared more quickly than the striatum for both. (11)C-d-Methamphetamine distribution volume ratio was not substantially affected by pretreatment with methamphetamine, methylphenidate, or tetrabenazine. Both enantiomers showed rapid, high uptake and clearance in the heart and lungs and slower uptake and clearance in the liver and kidneys. A comparison of (11)C-d-methamphetamine and (11)C-(-)-cocaine showed that (11)C-d-methamphetamine peaked later in the brain than did (11)C-(-)-cocaine and cleared more slowly. The 2 drugs showed similar behavior in all peripheral organs examined except the kidneys and pancreas, which showed higher uptake for (11)C-d-methamphetamine.

Conclusion: Brain pharmacokinetics did not differ between d-and l-methamphetamine and thus cannot account for the more intense stimulant effects of d-methamphetamine. Lack of pharmacologic blockade by methamphetamine indicates that the PET image represents nonspecific binding, though the fact that methamphetamine is both a transporter substrate and an inhibitor may also play a role. A comparison of (11)C-d-methamphetamine and (11)C-(-)-cocaine in the same animal showed that the slower clearance of methamphetamine is likely to contribute to its previously reported longer-lasting stimulant effects relative to those of (-)-cocaine. High kidney uptake of d-methamphetamine or its labeled metabolites may account for the reported renal toxicity of d-methamphetamine in humans.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Summed brain images for 11C-d-methamphetamine (top row, from 0–90 min) and 11C-l-(—)-cocaine (bottom row, from 0–54 min) in same animal. 11C distribution is widespread over cortical and subcortical brain regions for 11C-d-methamphetamine but is highly localized in striatum for 11C-(—)-cocaine. Images are coregistered to MRI atlas (20).
FIGURE 2
FIGURE 2
Time—activity curves for cortical and subcortical brain regions for 11C-d-methamphetamine (A) and 11C-l-methamphetamine (B) in same baboon (BEJ285dy1 and BEJ285dy2 refer to study number). Brain kinetics are similar for different brain regions.
FIGURE 3
FIGURE 3
Comparison of 11C-d-methamphetamine (A) and 11C-l-methamphetamine (B) distribution in peripheral organs in baboon (BEJ288dy1 and BEJ288dy2 refer to study number). 11C distribution is similar for the 2 enantiomers.
FIGURE 4
FIGURE 4
Time—activity curves for 11C-d-methamphetamine (A) and 11C-(—)-cocaine (B) in cerebellum and striatum in same baboon (BEJ298dy1 and BEJ298dy2 refer to study number). Clearance of 11C-d-methamphetamine is lower and slower than that of 11C-(—)-cocaine.
FIGURE 5
FIGURE 5
Comparison of distribution and clearance of 11C-d-methamphetamine (A) and 11C-(—)-cocaine (B) in peripheral organs in same baboon (BEJ303dy1 and BEJ303dy2 refer to study number). Both compounds show similar distribution and kinetics in heart, lungs, and liver, but d-methamphetamine has much greater uptake and slower clearance in kidneys and higher uptake in pancreas than does 11C-(—)-cocaine.

Similar articles

Cited by

References

    1. Barr AM, Panenka WJ, MacEqan W, et al. The need for speed: an update on MAMP addiction. J Psychiatry Neurosci. 2006;31:301–313. - PMC - PubMed
    1. Zhu JP, Xu W, Angulo JA. MAMP-induced cell death: selective vulnerability in neuronal subpopulations of the striatum in mice. Neuroscience. 2006;140:607–622. - PMC - PubMed
    1. Thompson PM, Hayashi KM, Simon KL, et al. Structural abnormalities in the brains of human subjects who use MAMP. J Neurosci. 2004;24:6028–6036. - PMC - PubMed
    1. Volkow ND, Chang L, Wang G-J, et al. Association of dopamine transporter reduction with psychomotor impairment in MAMP abusers. Am J Psychiatry. 2001;158:377–382. - PubMed
    1. Fitzmaurice PS, Tong J, Yazdanpanah M, Liu PP, Kalasinsky KS, Kish SJ. Levels of 4-hydroxynonenal and malondialdehyde are increased in brain of human chronic users of MAMP. J Pharmacol Exp Ther. 2006;319:703–709. - PubMed

Publication types